Acute electrophysiologic consequences of pyridostigmine inhibition of cholinesterase in humans

Brazilian Journal of Medical and Biological Research

Volumn 43, Issue 2, 2010, Pages 211-216

  Zimerman, L I ^a,b   Liberman, A ^a   Castro, R R T ^c   Ribeiro, J P ^a,b   Nobrega A C L ^c,d  

^a HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^b FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^c Departamento de Fisiologia e Farmacologia   (Brazil)

^d FLUMINENSE FEDERAL UNIVERSITY   (Brazil)

Author keywords

Autonomic nervous system; Cardiac electrophysiology; Cardiovascular disease; Cholinesterase inhibitors; Parasympathetic nervous system; Pyridostigmine bromide

Indexed keywords

CHOLINESTERASE; PYRIDOSTIGMINE;

ADULT; ARTICLE; CLINICAL ARTICLE; DRUG EFFECT; ENZYME INHIBITION; HEART CYCLE; HEART ELECTROPHYSIOLOGY; HEART MUSCLE REFRACTORY PERIOD; HEART PALPITATION; HEART RATE; HEART STIMULATION; HUMAN; MALE; SINUS RHYTHM; SYNCOPE; WENCKEBACH PERIOD;

EID: 76649137214     PISSN: 0100879X     EISSN: 1414431X     Source Type: Journal    
DOI: 10.1590/S0100-879X2010005000001     Document Type: Article

References (40)

1. La Rovere MT, Bigger JT Jr, Marcus FI, Mortara A, Schwartz PJ. Baroreflex sensitivity and heart-rate variability in prediction of total cardiac mortality after myocardial infarction. ATRAMI (Autonomic Tone and Reflexes After Myocardial Infarction) Investigators. Lancet 1998; 351: 478-484.
2. Schwartz PJ, La Rovere MT. ATRAMI: a mark in the quest for the prognostic value of autonomic markers. Autonomic Tone and Reflexes After Myocardial Infarction. Eur Heart J 1998; 19: 1593-1595.
3. Piepoli MF, Capucci A. Autonomic nervous system in the genesis of arrhythmias in chronic heart failure: implication for risk stratification. Minerva Cardioangiol 2007; 55: 325-333.
4. Hoyer D, Maestri R, La Rovere MT, Pinna GD. Autonomic response to cardiac dysfunction in chronic heart failure: a risk predictor based on autonomic information flow. Pacing Clin Electrophysiol 2008; 31: 214-220.
5. De Luca G, de Boer MJ, Ottervanger JP, van't Hof AW, Hoorntje JC, Gosselink AT, et al. Impact of beta-blocker therapy at discharge on long-term mortality after primary angioplasty for ST-segment elevation myocardial infarction. Am J Cardiol 2005; 96: 806-809.
6. Bigger JT Jr, Coromilas J. How do beta-blockers protect after myocardial infarction? Ann Intern Med 1984; 101: 256-258.
7. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med 1996; 334: 1349-1355.
8. Nobrega AC, Teixeira De Castro RR. Parasympathetic dysfunction as a risk factor in myocardial infarction: what is the treatment? Am Heart J 2000; 140: E23.
9. Kleiger RE, Miller JP, Bigger JT Jr, Moss AJ. Decreased heart rate variability and its association with increased mortality after acute myocardial infarction. Am J Cardiol 1987; 59: 256-262.
10. Odemuyiwa O, Malik M, Farrell T, Bashir Y, Poloniecki J, Camm J. Comparison of the predictive characteristics of heart rate variability index and left ventricular ejection fraction for all-cause mortality, arrhythmic events and sudden death after acute myocardial infarction. Am J Cardiol 1991; 68: 434-439.
11. Skeie GO, Apostolski S, Evoli A, Gilhus NE, Hart IK, Harms L, et al. Guidelines for the treatment of autoimmune neuromuscular transmission disorders. Eur J Neurol 2006; 13: 691-699.
12. Teichman SL, Ferrick A, Kim SG, Matos JA, Waspe LE, Fisher JD. Disopyramide-pyridostigmine interaction: selective reversal of anticholinergic symptoms with preservation of antiarrhythmic effect. J Am Coll Cardiol 1987; 10: 633-641.
13. Castro RR, Porphirio G, Serra SM, Nobrega AC. Cholinergic stimulation with pyridostigmine protects against exercise induced myocardial ischaemia. Heart 2004; 90: 1119-1123.
14. Castro RR, Serra SM, Porphirio G, Mendes FS, Oliveira LP, Nobrega AC. Pyridostigmine reduces QTc interval during recovery from maximal exercise in ischemic heart disease. Int J Cardiol 2006; 107: 138-139.
15. Nobrega AC, dos Reis AF, Moraes RS, Bastos BG, Ferlin EL, Ribeiro JP. Enhancement of heart rate variability by cholinergic stimulation with pyridostigmine in healthy subjects. Clin Auton Res 2001; 11: 11-17.
16. Nobrega AC, Loures DL, Pontes PV, Sant'anna ID, Mesquita ET. Cholinergic stimulation with pyridostigmine prevents the impairment in ventricular function during mental stress in coronary artery disease patients. Int J Cardiol 2008; 125: 418-421.
17. Behling A, Moraes RS, Rohde LE, Ferlin EL, Nobrega AC, Ribeiro JP. Cholinergic stimulation with pyridostigmine reduces ventricular arrhythmia and enhances heart rate variability in heart failure. Am Heart J 2003; 146: 494-500.
18. Castro RR, Serra SM, Nobrega AC. Reduction of QTc interval dispersion. Potential mechanism of cardiac protection of pyridostigmine bromide. Arq Bras Cardiol 2000; 75: 205-213.
19. Serra SM, Costa RV, Teixeira De Castro RR, Xavier SS, Nobrega AC. Cholinergic stimulation improves autonomic and hemodynamic profile during dynamic exercise in patients with heart failure. J Card Fail 2009; 15: 124-129.
20. Chowdhary S, Marsh AM, Coote JH, Townend JN. Nitric oxide and cardiac muscarinic control in humans. Hypertension 2004; 43: 1023-1028.
21. van Veldhuisen DJ. Disagreement between drug effects on autonomic function and mortality: another unreliable surrogate endpoint in heart failure? Int J Cardiol 2000; 75: 176-177.
22. Wit AL, Weiss MB, Berkowitz WD, Rosen KM, Steiner C, Damato AN. Patterns of atrioventricular conduction in the human heart. Circ Res 1970; 27: 345-359.
23. Levy MN, Zieske H. Autonomic control of cardiac pacemaker activity and atrioventricular transmission. J Appl Physiol 1969; 27: 465-470.
24. Markel ML, Miles WM, Zipes DP, Prystowsky EN. Parasympathetic and sympathetic alterations of Mobitz type II heart block. J Am Coll Cardiol 1988; 11: 271-275.
25. Prystowsky EN, Jackman WM, Rinkenberger RL, Heger JJ, Zipes DP. Effect of autonomic blockade on ventricular refractoriness and atrioventricular nodal conduction in humans. Evidence supporting a direct cholinergic action on ventricular muscle refractoriness. Circ Res 1981; 49: 511-518.
26. Prystowsky EN, Naccarelli GV, Jackman WM, Rinkenberger RL, Heger JJ, Zipes DP. Enhanced parasympathetic tone shortens atrial refractoriness in man. Am J Cardiol 1983; 51: 96-100.
27. Stein R, Medeiros CM, Rosito GA, Zimerman LI, Ribeiro JP. Intrinsic sinus and atrioventricular node electrophysiologic adaptations in endurance athletes. J Am Coll Cardiol 2002; 39: 1033-1038.
28. Josephson M. Clinical cardiac electrophysiology: techniques and interpretation. Philadelphia: Lea & Febiger; 1993.
29. Castro RR, Porphirio G, Serra SM, Nobrega AC. Cholinergic stimulation with pyridostigmine reduces the QTc interval in coronary artery disease. Braz J Med Biol Res 2002; 35: 685-689.
30. Deschamps A, Backman SB, Novak V, Plourde G, Fiset P, Chartrand D. Effects of the anticholinesterase edrophonium on spectral analysis of heart rate and blood pressure variability in humans. J Pharmacol Exp Ther 2002; 300: 112-117.
31. Stemple DR, Hall RJ, Mason JW, Harrison DC. Electrophysiologic effects of edrophonium in the innervated and the transplanted denervated human heart. Br Heart J 1978; 40: 644-649.
32. Watanabe S, Kono Y, Oishi-Tobinaga Y, Yamada S, Hara M, Kano T. A comparison of the chronotropic and dromotropic actions between adenosine triphosphate and edrophonium in patients undergoing coronary artery bypass graft surgery. J Cardiothorac Vasc Anesth 2002; 16: 598-602.
33. Miller RR, Olson HG, Vera Z, DeMaria AN, Amsterdam EA, Mason DT. Clinical evaluation of the enhancement of vagal tone in acute myocardial infarction by edrophonium hydrochloride: effects on ventricular arrhythmias, His bundle electrography, and left ventricular function. Am Heart J 1977; 93: 222-228.
34. Weiss T, Lattin GM, Engelman K. Vagally mediated suppression of premature ventricular contractions in man. Am Heart J 1975; 89: 700-707.
35. Mitrani RD, Kloosterman EM, Huikuri H, Dylewski J, Atapattu S, Interian A Jr, et al. Muscarinic receptor stimulation with edrophonium hydrochloride does not elevate ventricular fibrillation thresholds in humans. J Cardiovasc Electrophysiol 1999; 10: 809-816.
36. Nobrega AC, Carvalho AC, Bastos BG. Resting and reflex heart rate responses during cholinergic stimulation with pyridostigmine in humans. Braz J Med Biol Res 1996; 29: 1461-1465.
37. Raj SR, Black BK, Biaggioni I, Harris PA, Robertson D. Acetylcholinesterase inhibition improves tachycardia in postural tachycardia syndrome. Circulation 2005; 111: 2734-2740.
38. Hucker WJ, Nikolski VP, Efimov IR. Autonomic control and innervation of the atrioventricular junctional pacemaker. Heart Rhythm 2007; 4: 1326-1335.
39. Sampaio KN, Mauad H, Spyer KM, Ford TW. Differential chronotropic and dromotropic responses to focal stimulation of cardiac vagal ganglia in the rat. Exp Physiol 2003; 88: 315-327.
40. Schiereck P, Sanna N, Mosterd WL. AV blocking due to asynchronous vagal stimulation in rats. Am J Physiol Heart Circ Physiol 2000; 278: H67-H73.